“…This includes therapeutics with established efficacy in human disease (β 2 adrenoceptor agonists, anticholinergics, PDE inhibitors, steroids, cysLT 1 recceptor antagonists, 5-lipoxygenase/five lipoxygenase activating protein (FLAP) inhibitors) and therapeutics with modest or no beneficial effects in human disease, including anti-IL-5 antibodies, anti-TNF antibodies, and bradykinin, histamine, thromboxane and PAF receptor antagonists [9,10,20,21,35 -197,204,271-278]. A notable exception to this has been the many reports in guinea pigs showing beneficial effects of neurokinin receptor antagonists (see below).…”